Plaintiffs Challenging Myriad's Aussie BRCA Patent Will Appeal Federal Court's Dismissal of Case | GenomeWeb

Originally published Feb. 19.

Cancer Voices Australia, a patient group legally challenging Myriad Genetics' patent covering mutations in the BRCA1 gene linked to increased risk of hereditary breast and ovarian cancer, will likely appeal a federal court's recent decision to dismiss the case.

The Federal Court of Australia last week deemed that Myriad's patent on isolated gene sequences is valid under the country's laws outlining patentable subject matter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.